SCHEMBL127807

SCHEMBL127807

COc1ccc(-c2csc(N)n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 1.00
NPC1 O15118 6/20 1.00
MAPT P10636 5/20 1.00
ALDH1A1 P00352 5/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
POLB P06746 2/20 1.00
LTA4H P09960 5/20 0.82
ATP4A P20648 2/20 0.60
ATP4B P51164 2/20 0.60
KDM4E B2RXH2 2/20 0.59
ATM Q13315 1/20 0.59
PTGS2 P35354 1/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
LMNA P02545 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
MKNK1 Q9BUB5 1/20 0.59
MKNK2 Q9HBH9 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL8355367 0.98 RAB9A (0.96) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
Iodide SCHEMBL5455207 0.95 RAB9A (0.90) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL29654110 0.92 MAPT (0.84) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
Iodide SCHEMBL5461678 0.91 NPC1 (0.82) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL1771825 0.84 ALDH1A1 (0.79) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL23610361 0.82 ALDH1A1 (0.83) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL13394699 0.82 MAPT (0.73) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL5328219 0.81 ALDH1A1 (0.69) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL28931077 0.81 NPC1 (0.69) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL1180215 0.81 MAPT (0.84) RAB9ANPC1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001049686-A1 S-TRIAZINE DERIVATIVES AND THEIR USE AS UV FILTERS L'OREAL (FR) 2001-07-12 WO claimed
EP-0006368-B1 4-PHENYL-THIAZOLYL-2-OXAMATE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF ASTHMA PIERRE FABRE S.A. (FR) 1981-11-18 EP claimed
CN-120247900-A Phenyl thiazole amine pyrimidine derivative, and preparation method and application thereof 南京市鸿舜医药科技有限公司 2025-07-04 CN disclosed
US-20250051296-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2025-02-13 US disclosed
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-10-03 US disclosed
US-12103917-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-10-01 US disclosed
CN-118344304-A Ibuprofen derivative and preparation method and application thereof 华南农业大学 2024-07-16 CN disclosed
EP-3799871-B1 PYRAZOL-3-ONES THAT ACTIVATE PRO-APOTOTIC BAX DANA FARBER CANCER INST INC (US) 2024-02-28 EP disclosed
CN-116854683-A Coumarin thiazole derivative and preparation method and application thereof 中北大学 2023-10-10 CN disclosed
CN-113861186-B Isoxazole-based substituted benzamide derivative and application of anti-prostate cancer drug 浙江师范大学 2023-08-25 CN disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
EP-0161442-A2 Thiazolyl ureas, process for their preparation and their use to combat undesired plant growth BASF Aktiengesellschaft (DE) 1985-11-21 EP disclosed
US-4407810-A TREATMENT OF ALLERGIC DISORDERS BASF AKTIENGESELLSCHAFT (DE) 1983-10-04 US disclosed
EP-0044442-A1 N-(4-Phenyl-2-thiazolyl)-oxamidic-acid-2-ethoxyethylester, process for its preparation and pharmaceutical compositions containing this compound BASF Aktiengesellschaft (DE) 1982-01-27 EP disclosed
US-4246271-A ANTIALLERGENS PIERRE FABRE, S.A. (FR) 1981-01-20 US disclosed
US-4225610-A TREATMENT OF RHEUMATOID ARTHRITIS PIERRE FABRE, S.A. (FR) 1980-09-30 US disclosed
US-4207233-A Azo dyes containing a thiazole component BASF AKTIENGESELLSCHAFT (DE) 1980-06-10 US disclosed
US-4124581-A FOR NATURAL AND SYNTHETIC FIBERS, COLORFAST BAYER AKTIENGESELLSCHAFT (DE) 1978-11-07 US disclosed
US-4104268-A POLYACRYLONITRILE, POLYESTERS, POLYAMIDES BAYER AKTIENGESELLSCHAFT (DE) 1978-08-01 US disclosed
US-4006127-A Cationic diazacyanine dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 RAB9A 2879/4885NPC1 3091/4885MAPT 706/4885
US-20250051296-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF MYC, MYCBP, MLYCD RAB9A 3766/4885NPC1 187/4885MAPT 2121/4885
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN2, PSEN1, CHAT RAB9A 1895/4885NPC1 146/4885MAPT 13/4885
US-12103917-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof MYC, MYCBP, MLYCD RAB9A 3766/4885NPC1 187/4885MAPT 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.